Nicox S.A. (COX.PA)

0.988 €

-0.02 (-1.98%)
Rating:
Recommendation:
-
Symbol COX.PA
Price 0.988 €
Beta 1.042
Volume Avg. 0.08M
Market Cap 49.846M
Shares () -
52 Week Range 0.856-2.35
1y Target Est -
DCF Unlevered COX.PA DCF ->
DCF Levered COX.PA LDCF ->
ROE -21.67% Sell
ROA -17.93% Sell
Operating Margin -
Debt / Equity 63.49% Buy
P/E -
P/B 0.24 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Michele Garufi
Healthcare
Biotechnology
Paris

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.